Literature DB >> 16606835

Cysteinyl leukotriene 2 receptor and protease-activated receptor 1 activate strongly correlated early genes in human endothelial cells.

Barbara Uzonyi1, Katharina Lötzer, Steffen Jahn, Cornelia Kramer, Markus Hildner, Ellen Bretschneider, Dörte Radke, Michael Beer, Rüdiger Vollandt, Jilly F Evans, Colin D Funk, Andreas J R Habenicht.   

Abstract

Cysteinyl leukotrienes (cysLT), i.e., LTC4, LTD4, and LTE4, are lipid mediators derived from the 5-lipoxygenase pathway, and the cysLT receptors cysLT1-R/cysLT2-R mediate inflammatory tissue reactions. Although endothelial cells (ECs) predominantly express cysLT2-Rs, their role in vascular biology remains to be fully understood. To delineate cysLT2-R actions, we stimulated human umbilical vein EC with LTD4 and determined early induced genes. We also compared LTD4 effects with those induced by thrombin that binds to protease-activated receptor (PAR)-1. Stringent filters yielded 37 cysLT2-R- and 34 PAR-1-up-regulated genes (>2.5-fold stimulation). Most LTD4-regulated genes were also induced by thrombin. Moreover, LTD4 plus thrombin augmented gene expression when compared with each agonist alone. Strongly induced genes were studied in detail: Early growth response (EGR) and nuclear receptor subfamily 4 group A transcription factors; E-selectin; CXC ligand 2; IL-8; a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif 1 (ADAMTS1); Down syndrome critical region gene 1 (DSCR1); tissue factor (TF); and cyclooxygenase 2. Transcripts peaked at approximately 60 min, were unaffected by a cysLT1-R antagonist, and were superinduced by cycloheximide. The EC phenotype was markedly altered: LTD4 induced de novo synthesis of EGR1 protein and EGR1 localized in the nucleus; LTD4 up-regulated IL-8 formation and secretion; and LTD4 raised TF protein and TF-dependent EC procoagulant activity. These data show that cysLT2-R activation results in a proinflammatory EC phenotype. Because LTD4 and thrombin are likely to be formed concomitantly in vivo, cysLT2-R and PAR-1 may cooperate to augment vascular injury.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16606835      PMCID: PMC1458877          DOI: 10.1073/pnas.0601223103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  48 in total

1.  Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress.

Authors:  S F Yan; T Fujita; J Lu; K Okada; Y Shan Zou; N Mackman; D J Pinsky; D M Stern
Journal:  Nat Med       Date:  2000-12       Impact factor: 53.440

Review 2.  Prostaglandins and leukotrienes: advances in eicosanoid biology.

Authors:  C D Funk
Journal:  Science       Date:  2001-11-30       Impact factor: 47.728

3.  High-level expression of Egr-1 and Egr-1-inducible genes in mouse and human atherosclerosis.

Authors:  T A McCaffrey; C Fu; B Du; S Eksinar; K C Kent; H Bush; K Kreiger; T Rosengart; M I Cybulsky; E S Silverman; T Collins
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

Review 4.  Cysteinyl leukotriene receptors.

Authors:  Yiqun Hui; Colin D Funk
Journal:  Biochem Pharmacol       Date:  2002-12-01       Impact factor: 5.858

5.  Thrombin receptors activate G(o) proteins in endothelial cells to regulate intracellular calcium and cell shape changes.

Authors:  Jurgen F Vanhauwe; Tarita O Thomas; Richard D Minshall; Chinnaswamy Tiruppathi; Anli Li; Annette Gilchrist; Eun-ja Yoon; Asrar B Malik; Heidi E Hamm
Journal:  J Biol Chem       Date:  2002-05-30       Impact factor: 5.157

Review 6.  Thrombin signalling and protease-activated receptors.

Authors:  S R Coughlin
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

Review 7.  International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors.

Authors:  Charles Brink; Sven-Erik Dahlén; Jeffrey Drazen; Jilly F Evans; Douglas W P Hay; Simonetta Nicosia; Charles N Serhan; Takao Shimizu; Takehiko Yokomizo
Journal:  Pharmacol Rev       Date:  2003-03       Impact factor: 25.468

Review 8.  Leukotriene receptors: classification, gene expression, and signal transduction.

Authors:  Takashi Izumi; Takehiko Yokomizo; Hideru Obinata; Hideaki Ogasawara; Takao Shimizu
Journal:  J Biochem       Date:  2002-07       Impact factor: 3.387

9.  Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis.

Authors:  Rainer Spanbroek; Rolf Grabner; Katharina Lotzer; Markus Hildner; Anja Urbach; Katharina Ruhling; Michael P W Moos; Brigitte Kaiser; Tina U Cohnert; Thorsten Wahlers; Arthur Zieske; Gabriele Plenz; Horst Robenek; Peter Salbach; Hartmut Kuhn; Olof Radmark; Bengt Samuelsson; Andreas J R Habenicht
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

10.  Differential leukotriene receptor expression and calcium responses in endothelial cells and macrophages indicate 5-lipoxygenase-dependent circuits of inflammation and atherogenesis.

Authors:  Katharina Lötzer; Rainer Spanbroek; Markus Hildner; Anja Urbach; Regine Heller; Ellen Bretschneider; Helen Galczenski; Jilly F Evans; Andreas J R Habenicht
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-06-19       Impact factor: 8.311

View more
  28 in total

1.  Role of fibrinogen and protease-activated receptors in acute xenobiotic-induced cholestatic liver injury.

Authors:  James P Luyendyk; Nigel Mackman; Bradley P Sullivan
Journal:  Toxicol Sci       Date:  2010-10-25       Impact factor: 4.849

2.  Cysteinyl leukotriene 2 receptor promotes endothelial permeability, tumor angiogenesis, and metastasis.

Authors:  Ernest Duah; Lakshminarayan Reddy Teegala; Vinay Kondeti; Ravi K Adapala; Venkateshwar G Keshamouni; Yoshihide Kanaoka; K Frank Austen; Charles K Thodeti; Sailaja Paruchuri
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-17       Impact factor: 11.205

Review 3.  Leukotrienes and airway inflammation.

Authors:  Katsuhide Okunishi; Marc Peters-Golden
Journal:  Biochim Biophys Acta       Date:  2011-02-23

Review 4.  Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy.

Authors:  Gabrielle Fredman; Ira Tabas
Journal:  Am J Pathol       Date:  2017-06       Impact factor: 4.307

5.  Lipid mediator metabolic profiling demonstrates differences in eicosanoid patterns in two phenotypically distinct mast cell populations.

Authors:  Susanna L Lundström; Rohit Saluja; Mikael Adner; Jesper Z Haeggström; Gunnar Nilsson; Craig E Wheelock
Journal:  J Lipid Res       Date:  2012-10-03       Impact factor: 5.922

6.  Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression.

Authors:  R C Shelton; J Claiborne; M Sidoryk-Wegrzynowicz; R Reddy; M Aschner; D A Lewis; K Mirnics
Journal:  Mol Psychiatry       Date:  2010-05-18       Impact factor: 15.992

7.  Endothelial cysteinyl leukotriene 2 receptor expression mediates myocardial ischemia-reperfusion injury.

Authors:  Wei Jiang; Sean R Hall; Michael P W Moos; Richard Yang Cao; Satoshi Ishii; Kofo O Ogunyankin; Luis G Melo; Colin D Funk
Journal:  Am J Pathol       Date:  2008-02-14       Impact factor: 4.307

8.  Leukotriene D(4) induces gene expression in human monocytes through cysteinyl leukotriene type I receptor.

Authors:  Grzegorz Woszczek; Li-Yuan Chen; Sahrudaya Nagineni; Steven Kern; Jennifer Barb; Peter J Munson; Carolea Logun; Robert L Danner; James H Shelhamer
Journal:  J Allergy Clin Immunol       Date:  2007-10-29       Impact factor: 10.793

Review 9.  Eicosanoid lipid mediators in fibrotic lung diseases: ready for prime time?

Authors:  Steven K Huang; Marc Peters-Golden
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

10.  Leukotriene E4 elicits respiratory epithelial cell mucin release through the G-protein-coupled receptor, GPR99.

Authors:  Lora G Bankova; Juying Lai; Eri Yoshimoto; Joshua A Boyce; K Frank Austen; Yoshihide Kanaoka; Nora A Barrett
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.